Global Oncology Academy
The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
Episodes 16-30 of 51
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
MinuteCE®Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
MinuteCE®Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Emerging targeted therapy combination strategies in genitourinary malignancies
MinuteCE®Emerging targeted therapy combination strategies in genitourinary malignancies
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
MinuteCE®Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
MinuteCE®Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
MinuteCE®Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
MinuteCE®HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
MinuteCE®Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
MinuteCE®Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
Significance of HER2 Expression in Solid Tumors
MinuteCE®Significance of HER2 Expression in Solid Tumors
Diversity in HER2 Expression Among Gynecologic Cancers
MinuteCE®Diversity in HER2 Expression Among Gynecologic Cancers
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
MinuteCE®Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
Multiple Myeloma Care: Translating Evolving Practices to Oncology Nurses in Community Settings
CME/CEMultiple Myeloma Care: Translating Evolving Practices to Oncology Nurses in Community Settings
Multiple Myeloma Care: Translating Evolving Practices to Oncology Nurses in Community Settings
CME/CE Broadcast ReplayMultiple Myeloma Care: Translating Evolving Practices to Oncology Nurses in Community Settings
